In other diseases, such as cancer, AT13148 AGC kinase inhibitor, which potentially inhibits ROCK and AKT kinases and inhibits proliferative and metastatic activity in preclinical models, was clinically tried in oral administration [341]. Here, AKT1 is linked to cancer.